Edition:
United Kingdom

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

1.64USD
4:09pm BST
Change (% chg)

$-0.06 (-3.53%)
Prev Close
$1.70
Open
$1.68
Day's High
$1.71
Day's Low
$1.63
Volume
10,453
Avg. Vol
94,997
52-wk High
$2.58
52-wk Low
$0.90

Chart for

About

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that... (more)

Overall

Beta: 3.01
Market Cap(Mil.): $98.79
Shares Outstanding(Mil.): 59.88
Dividend: --
Yield (%): --

Financials

  EYES.OQ Industry Sector
P/E (TTM): -- 35.20 32.31
EPS (TTM): -0.53 -- --
ROI: -299.70 14.20 12.97
ROE: -299.70 16.94 14.84

BRIEF-Second Sight Medical Products Says Robert Greenberg's Resignation "Was An Outgrowth Of A Disagreement Over His Reporting Relationship" With Co

* FORMER CHAIMAN ROBERT GREENBERG'S RESIGNATION "WAS AN OUTGROWTH OF A DISAGREEMENT OVER HIS REPORTING RELATIONSHIP" WITH CO

09 Apr 2018

BRIEF-Second Sight Appoints John Blake Chief Financial Officer

* SECOND SIGHT APPOINTS JOHN T. BLAKE CHIEF FINANCIAL OFFICER

22 Mar 2018

BRIEF-Second Sight Appoints Gregg Williams As Chairman Of The Board Of Directors

* SECOND SIGHT APPOINTS GREGG WILLIAMS AS CHAIRMAN OF THE BOARD OF DIRECTORS

16 Mar 2018

BRIEF-Second Sight Q4 Loss Per Share $0.13

* SECOND SIGHT REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

07 Mar 2018

BRIEF-Second Sight Announces Market Entry Into Singapore With First Implant Of Argus II Retinal Prosthesis System

* SECOND SIGHT ANNOUNCES MARKET ENTRY INTO SINGAPORE WITH FIRST IMPLANT OF ARGUS II RETINAL PROSTHESIS SYSTEM Source text for Eikon: Further company coverage:

16 Feb 2018

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

08 Nov 2017

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

02 Nov 2017

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

31 Oct 2017

Earnings vs. Estimates